FDA approves Horizant to treat restless legs syndrome

Posted by Food and Drug Administration--Press Releases on Thursday Apr 7, 2011 Under News

On April 6, the U.S. Food and Drug Administration approved Horizant Extended Release Tablets (gabapentin enacarbil), a once-daily treatment for moderate-to-severe restless legs syndrome (RLS).

Be Sociable, Share!

Comments are closed.